KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Share-based Compensation (IS)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

BioNTech SE (BNTX) EBITDA (2018 - 2025)

BioNTech SE's EBITDA history spans 8 years, with the latest figure at -$375.8 million for Q4 2025.

  • On a quarterly basis, EBITDA fell 336.63% to -$375.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.4 billion, a 50.58% decrease, with the full-year FY2025 number at -$1.6 billion, down 13.02% from a year prior.
  • EBITDA hit -$375.8 million in Q4 2025 for BioNTech SE, down from -$54.8 million in the prior quarter.
  • Over the last five years, EBITDA for BNTX hit a ceiling of $5.6 billion in Q3 2021 and a floor of -$985.8 million in Q2 2024.
  • Historically, EBITDA has averaged $1.5 billion across 5 years, with a median of $385.7 million in 2024.
  • Biggest five-year swings in EBITDA: soared 5574.02% in 2021 and later crashed 336.63% in 2025.
  • Tracing BNTX's EBITDA over 5 years: stood at $5.4 billion in 2021, then tumbled by 37.51% to $3.4 billion in 2022, then tumbled by 83.15% to $566.2 million in 2023, then tumbled by 71.95% to $158.8 million in 2024, then plummeted by 336.63% to -$375.8 million in 2025.
  • Business Quant data shows EBITDA for BNTX at -$375.8 million in Q4 2025, -$54.8 million in Q3 2025, and -$481.1 million in Q2 2025.